TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma today and set a price target of $482.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ritu Baral has given her Buy rating due to a combination of factors including Alnylam Pharma’s impressive financial performance and strategic advancements. The company’s second-quarter 2025 net product revenue significantly exceeded expectations, driven primarily by the strong sales of Amvuttra, which outperformed consensus estimates. This robust revenue growth has led Alnylam to raise its full-year revenue guidance, indicating confidence in continued market expansion and product demand.
Additionally, Alnylam is on track to achieve GAAP breakeven in 2025, supported by increased revenue projections and strategic partnerships. The company’s collaborations and royalty agreements, particularly with major firms like Roche and REGN, further bolster its financial outlook. These elements combined suggest a promising growth trajectory for Alnylam, justifying the Buy rating from Ritu Baral.
Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and Alnylam Pharma. According to TipRanks, Baral has an average return of 11.7% and a 49.70% success rate on recommended stocks.